Ardelyx Inc
ARDX6.420USD
+0.230+3.72%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
1.55BMarket Cap
LossP/E TTM
More Details of Ardelyx Inc Company
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Company Info
Ticker SymbolARDX
Company nameArdelyx Inc
IPO dateJun 19, 2014
CEOMr. Michael G. (Mike) Raab
Number of employees395
Security typeOrdinary Share
Fiscal year-endJun 19
Address400 Fifth Avenue
CityWALTHAM
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02451
Phone15107451700
Websitehttps://www.ardelyx.com/
Ticker SymbolARDX
IPO dateJun 19, 2014
CEOMr. Michael G. (Mike) Raab
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
431.46K
-9.58%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
298.87K
-4.87%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
Dr. Merdad Parsey, M.D., Ph.D.
Dr. Merdad Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Kelliher
Mr. Mike Kelliher
Chief Business Officer
Chief Business Officer
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Independent Director
Independent Director
--
--
Dr. Laura Williams, M.D.
Dr. Laura Williams, M.D.
Chief Medical Officer, Chief Patient Officer
Chief Medical Officer, Chief Patient Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
431.46K
-9.58%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
298.87K
-4.87%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
IBSRELA
44.40M
0.00%
XPHOZAH
23.41M
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
IBSRELA
44.40M
0.00%
XPHOZAH
23.41M
0.00%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.80%
The Vanguard Group, Inc.
6.63%
Janus Henderson Investors
6.25%
Millennium Management LLC
4.84%
Macquarie Investment Management
4.75%
Other
70.73%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.80%
The Vanguard Group, Inc.
6.63%
Janus Henderson Investors
6.25%
Millennium Management LLC
4.84%
Macquarie Investment Management
4.75%
Other
70.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.68%
Investment Advisor/Hedge Fund
24.00%
Hedge Fund
13.25%
Research Firm
5.13%
Individual Investor
2.59%
Pension Fund
0.45%
Bank and Trust
0.33%
Family Office
0.08%
Insurance Company
0.04%
Other
26.46%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
461
180.23M
74.79%
+5.74M
2025Q1
470
173.66M
72.61%
+2.64M
2024Q4
452
158.29M
66.42%
-9.57M
2024Q3
441
149.04M
63.31%
-41.81M
2024Q2
420
152.02M
64.97%
-36.87M
2024Q1
399
149.36M
64.27%
-40.02M
2023Q4
363
143.31M
61.82%
-29.22M
2023Q3
347
131.10M
60.21%
-55.04M
2023Q2
355
129.77M
60.57%
-68.74M
2023Q1
359
119.15M
57.99%
-45.93M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
15.88M
6.64%
-651.24K
-3.94%
Mar 31, 2025
The Vanguard Group, Inc.
14.94M
6.25%
+634.58K
+4.44%
Mar 31, 2025
Janus Henderson Investors
24.98M
10.44%
+589.07K
+2.42%
Mar 31, 2025
Millennium Management LLC
12.10M
5.06%
+5.63M
+87.15%
Jun 17, 2025
Macquarie Investment Management
11.16M
4.66%
+811.55K
+7.84%
Mar 31, 2025
Marshall Wace LLP
8.38M
3.5%
+8.27M
+7201.76%
Mar 31, 2025
State Street Global Advisors (US)
10.18M
4.25%
-1.42M
-12.22%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.67M
2.37%
+162.88K
+2.96%
Mar 31, 2025
Nuveen LLC
3.39M
1.42%
+1.24M
+57.47%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
